Cole Ryan 4

What Happened

• Cole Ryan, Chief Operating Officer of Aurinia Pharmaceuticals (AUPH), received equity awards on 2026-05-18 totaling 186,374 units: 116,144 performance stock units (PSUs) and 70,230 time‑based restricted stock units (RSUs). The Form 4 reports an acquisition price of $0.00 for both grants (typical for compensation awards). These are awards (compensation), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-20 (timely).
• Reported acquisition price: $0.00 for both grants.
• Total awarded: 186,374 units (116,144 PSUs + 70,230 RSUs).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote F1 (PSUs): Each PSU is a contingent right to one common share. 46,820 of the PSUs vest in four tranches upon the stock hitting four escalating price targets (each tranche subject to a one‑year retention period). 69,324 of the PSUs vest in two tranches at the 3‑ and 5‑year anniversaries if target prices are met before vesting.
• Footnote F2 (time‑based RSUs): 33% of these RSUs vest on the 1‑year anniversary of the grant; the remaining 67% vest equally in monthly installments over the following two years.
• Transaction type: Award/Grant (code A) — compensation, not a buy/sell.

Context

• These awards are compensation and include performance‑based PSUs (which only convert to shares if price/vesting conditions are met) and standard time‑based RSUs. They do not represent an immediate cash purchase or sale of stock and therefore are not direct expressions of short‑term trading intent.